NSE: SUPRIYA · BSE: 543434
SUPRIYA LIFESCIENCE LTD
Manufactures active pharmaceutical ingredients (APIs), with a global position in anti-histamines and related therapies. The anaesthetic segment contributed 54% of Q4 FY26 revenues, and a Liquid Anesthetic product was commercialised during the year. The business is heavily export-oriented: 82% of revenue comes from exports across 120+ countries, with Europe at 40% of revenue, Asia at 33%, and Latin America at 20%. Backward integration covers 76% of revenue, supporting in-house supply of starting materials and intermediates. Five finished dosage manufacturing lines were commissioned at the Ambernath facility, marking entry into formulations alongside the core API operations at Lote, where capacity utilisation improved to 74% from 70%. The R&D pipeline includes 30 products in development, including a patented novel Semaglutide formulation, and the business is expanding into CDMO/CMO services. Materials account for 32% of revenue, the largest cost line, while capex ran at 18.4% of revenue in FY26. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. API manufacturing, Anaesthetics (54%), Finished dosages, CDMO/CMO services. Asset-heavy, export-oriented API manufacturer with high backward integration
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 530 | 461 | 570 | 696 | 828 |
| EBITDA (ex other income) | 214 | 129 | 173 | 261 | 294 |
| margin % | 40.4 | 28.0 | 30.3 | 37.4 | 35.5 |
| Owners' profit | 152 | 90 | 119 | 188 | 209 |
| EPS, as reported (₹) | 18.86 | 11.16 | 14.80 | 23.35 | 25.98 |
| ROE % · ROCE % | 24.7 · 33.3 | 12.8 · 17.5 | 14.6 · 19.9 | 18.9 · 24.3 | 17.5 · 22.4 |
| Debt / equity (x) | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 49 | 66 | 113 | 165 | 186 |
| Capex | (60) | (108) | (146) | (162) | (152) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 |
| Profit before tax | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 |
| Net profit | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 |
| EPS (₹) | 5.71 | 5.82 | 6.29 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 34.6 | 30.1 | 89 of 158 | 44% |
| P/B | 5.7 | 3.0 | 127 of 163 | 22% |
| ROCE | 22.2 | 10.8 | 24 of 183 | 87% |
| ROE | 17.5 | 9.8 | 30 of 166 | 82% |
| Debt / Equity | 0.0 | 0.2 | 1 of 166 | 79% |
| EBITDA margin | 26.4 | 17.5 | 46 of 165 | 73% |
| Revenue growth | 30.8 | 16.3 | 45 of 161 | 73% |
| Profit growth | (30.9) | 30.9 | 120 of 158 | 24% |
| Market cap | 6859 | 810 | 50 of 181 | 73% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 19 Oct 2026 · Supreme Court admits case; no coercive action against Supriya Lifescience directors | regulatory legal | high | — | — |
| 13 Oct 2026 · Supriya Lifescience gets CRISIL ESG rating of 65 in Strong category | credit debt | medium | — | — |
| 12 Oct 2026 · Routine RTA compliance certificate filed for July to September 2026 quarter | compliance | minimal | — | — |
| 8 Oct 2026 · Filed petition before Supreme Court in ongoing judicial matter | regulatory legal | high | — | — |
| 28 Sept 2026 · Trading Window closed from Oct 1 until 48 hours after Q2 results | compliance | minimal | — | — |
| 25 Sept 2026 · Supriya Lifescience 18th AGM: All 5 resolutions passed, Re.1 dividend approved | board shareholder meetings | low | — | — |
| 23 Sept 2026 · Court allows provisional release of 200 kg Ketamine consignment, subject to deposit | general | medium | — | — |
| 23 Sept 2026 · Supriya Lifescience explains missing segment details in Q1 results | regulatory legal | medium | — | — |
| 20 Sept 2026 · Supriya Lifescience to meet analysts on Sept 25 | board shareholder meetings | low | — | — |
| 20 Sept 2026 · Supriya Lifescience schedules virtual analyst group meeting on Sep 25 | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.